Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00861341 · ClinicalTrials.gov registry record · Phase 2

Effects of Pioglitazone on Platelet Function

A Phase 2 study, sponsored by University of Rochester.

Completed
Registry status
Phase 2
Development phase
40
Enrollment target

NCT00861341 is a Phase 2 study that has completed, run by University of Rochester. The registered enrollment target is 40 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00861341, a Phase 2 study, has completed, sponsored by University of Rochester.

COMPLETED
Registry status
Phase 2
Development phase
40 participants
Enrollment target

Study Summary

The purpose of this study is to determine how pioglitazone and aspirin affect platelets in the blood of diabetic and non-diabetic subjects. Platelets are small cells in the blood that help with blood clotting. Pioglitazone is a drug that is used to lower blood sugar and fats by helping the body to use insulin correctly. Pioglitazone is presently used to treat diabetes but has not been approved for non-diabetics. This study will determine whether pioglitazone reduces the activity of platelets in people who are or are not also taking aspirin.

Interventions

  • DRUG Aspirin
  • DRUG Pioglitazone

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2008-12
Est. Completion 2011-06
Phase Phase 2

Sponsor

University of Rochester

636 total trials

What the Registry Record Tells You About NCT00861341

The ClinicalTrials.gov registry entry for NCT00861341 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Aspirin is the first listed.

NCT00861341 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00861341 about?

NCT00861341 is a clinical study titled "Effects of Pioglitazone on Platelet Function". The purpose of this study is to determine how pioglitazone and aspirin affect platelets in the blood of diabetic and non-diabetic subjects. Platelets are small cells in the blood that help with blood clotting. Pioglitazone is a drug that is used to lower blood sugar and fats by helping the body to u...

What is the current status of trial NCT00861341?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2008-12. Estimated completion is 2011-06.

What interventions are being tested in trial NCT00861341?

The interventions under investigation include: Aspirin (DRUG), Pioglitazone (DRUG).

Who is sponsoring clinical trial NCT00861341?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.